Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-31

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a 12-week (in addition to up to 30 days of screening) randomized, double-blind, placebo-controlled, parallel-group trial. The primary objective of this study is to assess the effectiveness, safety, and tolerability of single-dose psilocybin (25 mg)-assisted therapy in comparison to active placebo (1 mg micro-dose) psilocybin-assisted therapy in patients with bipolar II depression who have not responded to adequate trials with at least two first or second-line treatments for bipolar II depression (i.e. quetiapine, lithium, lamotrigine, sertraline, or venlafaxine as monotherapy or adjunctive therapy, or bupropion adjunctive therapy). The active placebo is a substance that looks identical to the study medication but contains less therapeutic ingredients, and thus is less capable of producing the transformative and meaningful aspects of psychedelic experience compared to the 25 mg dose. Participants will have a total of 11 study visits over a period of up to 16 weeks, which includes 5 therapy sessions from trained study therapists.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

NCT04433845

Treatment Resistant Depression

UNKNOWN PHASE2

Psilocybin Therapy for Depression in Bipolar II Disorder

NCT05065294

Bipolar II Disorder

ACTIVE_NOT_RECRUITING PHASE2

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression

NCT06506019

Bipolar Depression

RECRUITING PHASE1

Lamotrigine Alone Compared to Lamotrigine Plus Antidepressant for the Treatment of Bipolar II Depression

NCT00475137

Bipolar II Disorder, Most Recent Episode Major Depressive

COMPLETED PHASE2

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

NCT06706232

Bipolar II Disorder Depression, Bipolar Suicidality

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bipolar disorders (BD) are lifelong conditions characterized by recurrent episodes of depression and (hypo)mania. Statistics Canada data indicate over a million Canadians are affected by this illness. Bipolar II disorder is characterised by recurrent episodes of hypomania and depression and individuals with BD-II are symptomatic about 50% of the time despite treatment. The majority of this time is spent being depressed thus there is an urgent need to develop new treatments that are safe and effective. Psilocybin, a naturally occurring psychedelic compound found in mushrooms, has been noted to result in an increase in psychological well-being in healthy volunteers as well as have antidepressant effects when administered in conjunction with psychological support. Two recent open-label pilot trials of Psilocybin-Assisted Therapy (PAT) in treatment-resistant depression, including BD-II participants, demonstrated high response rates and excellent tolerability, thereby providing strong justification for the current study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar II Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Double-blind, Active Placebo controlled, Randomized Clinical Trial

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Therapist

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active

25 mg psilocybin.

Group Type EXPERIMENTAL

psilocybin (25 mg)

Intervention Type DRUG

Single-dose psilocybin (25 mg)-assisted therapy (PAT)

Placebo

1 mg psilocybin (micro-dose)

Group Type PLACEBO_COMPARATOR

psilocybin 1mg micro-dose

Intervention Type DRUG

Single dose active placebo psilocybin-assisted therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

psilocybin (25 mg)

Single-dose psilocybin (25 mg)-assisted therapy (PAT)

Intervention Type DRUG

psilocybin 1mg micro-dose

Single dose active placebo psilocybin-assisted therapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. You are male or female aged 19 to 65 years inclusive.
2. You have a diagnosis of bipolar disorder type II, and are currently in a major depressive episode.
3. You are willing, for the entire duration of the study, to practice highly effective methods of contraception (e.g., contraceptive pills, intrauterine device or system, vasectomy and tubal ligation, or double-barrier methods of contraception) OR agree to completely abstain from heterosexual intercourse. Females who do not have childbearing potential are required to be postmenopausal for at least 1 year before the screening visit (confirmed by an FSH test) OR surgically sterile.
4. You have sufficient English language skills to understand, consent to, and comply with study requirements, study visits, and to return to the clinic for follow-up evaluations.
5. Your current medications have been at a stable dose for two weeks prior to the dosing visit.

Exclusion Criteria

1. You have a history of psychotic symptoms.
2. You have a history of seizures.
3. You have a current unstable or inadequately treated medical illness, especially cardiovascular illness, except for the current depression.
4. You recently (i.e., within the past 6 weeks) started taking treatment for your acute bipolar depressive episode.
5. You recently (i.e., within the past 8 weeks) began structured psychotherapy (e.g., cognitive-behavioral therapy, interpersonal psychotherapy, family-focused therapy, or interpersonal and social rhythm therapy).
6. You have a history of nonresponse or intolerance to psilocybin.
7. You have, in the past 6 months, used any psychedelic drugs, including ketamine, LSD, or psilocybin-containing mushrooms.
8. You have a history of non-response to electroconvulsive therapy.
9. You are pregnant or lactating.

Minimum Eligible Age

19 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No